TY - JOUR
T1 - Evaluation of the combined effect of pranlukast during high-dose steroid inhalation
AU - Horiguchi, Takahiko
AU - Tachikawa, Soichi
AU - Kondo, Rieko
AU - Miyazaki, Junichi
AU - Sasaki, Yasushi
AU - Banno, Kengo
AU - Handa, Misuzu
PY - 2002
Y1 - 2002
N2 - In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon®) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.
AB - In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon®) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.
UR - http://www.scopus.com/inward/record.url?scp=0036440506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036440506&partnerID=8YFLogxK
U2 - 10.1055/s-0031-1299972
DO - 10.1055/s-0031-1299972
M3 - Article
C2 - 12489251
AN - SCOPUS:0036440506
SN - 0004-4172
VL - 52
SP - 813
EP - 816
JO - Arzneimittel-Forschung/Drug Research
JF - Arzneimittel-Forschung/Drug Research
IS - 11
ER -